EDEN PRAIRIE, Minn., March 28, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), today announced it will be exhibiting at
the 2019 Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) on April
3-6, 2019 at the Lowes Meeting Complex in Orlando, Fla. The company can be found on the exhibition floor at booth #408.
“We continue to expand our reach within the cardiovascular community in order to demonstrate the value of ultrafiltration
therapy in post-operative cardiac surgery. We recently announced the additional focus of using the Aquadex Flex Flow system
post-surgery, and we believe that the ISHLT is an excellent opportunity to increase awareness,” said John Erb, chairman and CEO of
CHF Solutions.
About the ISHLT
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional
organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical
support and innovative therapies via research, education and advocacy. The purposes of the Society are: promoting the
association of persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related
sciences; encouraging and stimulating basic and clinical research in heart and lung transplantation and end-stage heart and lung
disease, and promoting new therapeutic strategies; holding scientific meetings featuring presentations and discussions relevant to
heart and lung transplantation and the treatment of end-stage heart and lung disease; sponsoring a scientific journal for the
publication of manuscripts related to these disciplines; maintaining an international registry for heart and lung transplantation;
awarding research grants and establishing endowments for the study of heart and lung transplantation and end-stage heart and lung
disease, when funds are available and without jeopardizing the financial well-being of the organization; and sponsoring and
conducting educational activities and providing educational resources, which promote expert development and improve standards of
care in advanced heart and lung disease, heart and lung transplantation, and relevant medical and device therapies.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow® system for
aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be
administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal
therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration,
and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis,
Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the
Nasdaq Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including without limitation, the company’s plans for the Society of Thoracic Surgeons Annual
Meeting. Forward-looking statements are predictions, projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause
actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those
risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient
funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to
patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and
other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the
date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
